Johnson & Johnson agreed Monday to a landmark $5.5 billion settlement resolving approximately 76,000 lawsuits claiming the company's talc products, including baby powder, caused ovarian cancer. The deal could finally close out a legal war that has consumed the New Jersey healthcare giant for more than a decade.
The settlement covers claims consolidated in federal court in New Jersey and related cases in state court, representing nearly all remaining talc litigation against the company. For the agreement to take effect, it must win approval from at least 95 percent of ovarian cancer claimants across both state and federal cases.
Johnson & Johnson's vice president of litigation, Erik Haas, characterized the settlement as a way to achieve closure rather than an admission of wrongdoing. The company maintains the claims are without merit but determined that resolving the dispute was preferable to continuing litigation.
"While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives," Haas said.
The payment schedule stretches across two years, with $3 billion due in 2027 and additional funds in 2028. However, the total could exceed $5.5 billion depending on participation levels. Chris Seeger, a plaintiff attorney who negotiated the agreement and represents roughly 2,500 talc claimants, estimates the ultimate payout could reach $7 billion or higher.
Seeger emphasized that the settlement assigns specific dollar values to qualifying ovarian cancer claims without capping the company's total liability. He characterized the outcome as fair and predicted client satisfaction.
The settlement arrives after a string of courtroom victories shifted momentum decisively in Johnson & Johnson's favor. The company won multiple individual trials, successfully moved to disqualify opposing counsel from the case, and achieved court rulings that undermined key expert testimony plaintiffs relied on. Last week, a federal judge ruled skeptically on whether individual plaintiffs could prove talc specifically caused their cancers, a decision that substantially weakened the remaining cases.
Johnson & Johnson halted U.S. sales of talc-based baby powder in 2020, replacing it with cornstarch alternatives. Legal action had paused for more than three years while the company attempted an aggressive bankruptcy strategy, filing three separate bankruptcy petitions through a subsidiary company. Each filing was dismissed, clearing the way for litigation to resume in March 2025.
Before the bankruptcy experiments, the company experienced mixed results in the courtroom. A jury awarded a multibillion-dollar verdict in favor of 22 women claiming baby powder caused their ovarian cancer. Other trials produced outright victories or verdicts reduced on appeal, creating uncertainty about the company's ultimate exposure.
Unlike the failed bankruptcy proposals, Monday's agreement applies solely to existing claims and explicitly excludes future lawsuits. This structure accelerated the payment timeline, compressing claims resolution into 18 months rather than spreading payments across more than a decade, giving current plaintiffs access to funds faster than previous settlement proposals offered.
Author James Rodriguez: "This settlement shows how much litigation risk and courtroom momentum shifted in J&J's favor, but paying billions to walk away beats the unpredictability of years more trials."
Comments